Literature DB >> 23999322

Viral hepatitis: Treating hepatitis C in injection drug users.

Vincent Soriano1, Lucía Gallego.   

Abstract

A large proportion of hepatitis C in the developed world occurs in injection drug users. Treatment uptake in this population is low, despite the rising burden of HCV-related liver disease. Multiple barriers preclude the optimal care of hepatitis C in injection drug users, including low medication adherence and HCV re-infection.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23999322     DOI： 10.1038/nrgastro.2013.165

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.

Authors:  Pascal Melin; Michel Chousterman; Thierry Fontanges; Denis Ouzan; Michel Rotily; Jean-Philippe Lang; Patrick Marcellin; Patrice Cacoub
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-09       Impact factor: 2.566

Review 2.  Hepatitis C treatment for injection drug users: a review of the available evidence.

Authors:  Margaret Hellard; Rachel Sacks-Davis; Judy Gold
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

Review 3.  Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.

Authors:  Vincent Soriano; Kenneth E Sherman; Juergen Rockstroh; Douglas Dieterich; David Back; Mark Sulkowski; Marion Peters
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

4.  The changing face of hepatitis C in the new era of direct-acting antivirals.

Authors:  Vincent Soriano; Pablo Labarga; Jose V Fernández-Montero; Jose M Benito; Eva Poveda; Norma Rallon; Clara Sánchez; Eugenia Vispo; Pablo Barreiro
Journal:  Antiviral Res       Date:  2012-11-09       Impact factor: 5.970

Review 5.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

6.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Geert Robaeys; Jason Grebely; Stefan Mauss; Philip Bruggmann; Joseph Moussalli; Andrea De Gottardi; Tracy Swan; Amber Arain; Achim Kautz; Heino Stöver; Heiner Wedemeyer; Martin Schaefer; Lynn Taylor; Markus Backmund; Olav Dalgard; Maria Prins; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 7.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

Review 8.  Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection.

Authors:  Lucía Gallego; Pablo Barreiro; Juan José López-Ibor
Journal:  AIDS Rev       Date:  2011 Jul-Sep       Impact factor: 2.500

9.  Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.

Authors:  Mark S Sulkowski; Kenneth E Sherman; Douglas T Dieterich; Mohammad Bsharat; Lisa Mahnke; Jürgen K Rockstroh; Shahin Gharakhanian; Scott McCallister; Joshua Henshaw; Pierre-Marie Girard; Bambang Adiwijaya; Varun Garg; Raymond A Rubin; Nathalie Adda; Vincent Soriano
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

10.  Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Authors:  Mark Sulkowski; Stanislas Pol; Josep Mallolas; Hugo Fainboim; Curtis Cooper; Jihad Slim; Antonio Rivero; Carmen Mak; Seth Thompson; Anita Y M Howe; Larissa Wenning; Peter Sklar; Janice Wahl; Wayne Greaves
Journal:  Lancet Infect Dis       Date:  2013-06-12       Impact factor: 25.071
  10 in total
  7 in total

Review 1.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

Review 2.  Current and future challenges in HCV: insights from an Italian experts panel.

Authors:  Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì
Journal:  Infection       Date:  2017-11-02       Impact factor: 3.553

Review 3.  Pre-Exposure Prophylaxis for viral infections other than HIV.

Authors:  Vicente Soriano; Ana Treviño; Carmen de Mendoza; Víctor Moreno-Torres; Ilduara Pintos; Pablo Barreiro; Octavio Corral
Journal:  Infez Med       Date:  2022-09-01

Review 4.  The use of technology-based adherence monitoring in the treatment of hepatitis C virus.

Authors:  Yeba H Adje; Kristina M Brooks; Jose R Castillo-Mancilla; David L Wyles; Peter L Anderson; Jennifer J Kiser
Journal:  Ther Adv Infect Dis       Date:  2022-05-13

Review 5.  HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.

Authors:  Kazuaki Chayama; C Nelson Hayes
Journal:  Viruses       Date:  2015-10-13       Impact factor: 5.048

Review 6.  AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.

Authors:  Vicente Soriano; José M Ramos; Pablo Barreiro; Jose V Fernandez-Montero
Journal:  Viruses       Date:  2018-05-30       Impact factor: 5.048

7.  Hepatitis C virus prevention and care for drug injectors: the French approach.

Authors:  Jean-Michel Delile; Victor de Ledinghen; Marie Jauffret-Roustide; Perrine Roux; Brigitte Reiller; Juliette Foucher; Daniel Dhumeaux
Journal:  Hepatol Med Policy       Date:  2018-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.